Renaissance Technologies LLC Invests $176,000 in Cellectar Biosciences Inc (CLRB)

Renaissance Technologies LLC purchased a new stake in Cellectar Biosciences Inc (NASDAQ:CLRB) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 58,553 shares of the biopharmaceutical company’s stock, valued at approximately $176,000. Renaissance Technologies LLC owned approximately 1.63% of Cellectar Biosciences as of its most recent SEC filing.

Shares of NASDAQ CLRB opened at $1.81 on Wednesday. Cellectar Biosciences Inc has a fifty-two week low of $1.22 and a fifty-two week high of $14.00. The stock has a market cap of $9.13 million, a P/E ratio of -0.17 and a beta of 1.25.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Tuesday, November 13th. The biopharmaceutical company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.82). On average, research analysts predict that Cellectar Biosciences Inc will post -4.84 EPS for the current year.

Separately, Brookline Capital Management restated a “buy” rating on shares of Cellectar Biosciences in a research note on Tuesday, November 20th.

COPYRIGHT VIOLATION NOTICE: “Renaissance Technologies LLC Invests $176,000 in Cellectar Biosciences Inc (CLRB)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2019/02/13/renaissance-technologies-llc-invests-176000-in-cellectar-biosciences-inc-clrb.html.

Cellectar Biosciences Profile

Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies.

Featured Story: What is the QQQ ETF?

Want to see what other hedge funds are holding CLRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectar Biosciences Inc (NASDAQ:CLRB).

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit